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AbstrAct
This paper summarises the first consensus 
guidelines for idiopathic intracranial hypertension 
as an infographic. Following a systematic 
literature review, a multidisciplinary specialist 
interest group met and established questions 
relating to population, interventions, controls 
and outcomes (PICO). A survey was sent to 
doctors who manage idiopathic intracranial 
hypertension (IIH) regularly. Statements 
were reviewed by national professional 
bodies, specifically the Association of British 
Neurologists, British Association for the 
Study of Headache, the Society of British 
Neurological Surgeons and the Royal College 
of Ophthalmologists and by international 
experts. Key areas are represented based 
on the guideline, namely: (1) investigation 
of papilloedema and diagnosis of IIH; (2) 
management strategies; and (3) investigation 
and management of acute exacerbation of 
headache in established IIH. We present an 
infographic as an aide-mémoire of the first 
consensus guidelines for IIH.
IIH is commonly associated with obesity, 
younger age and females.1 2 Patients 
present acutely to many different special-
ities and often have multiple acute visits 
through the course of their disease. The 
investigation and management of IIH is 
complex involving many specialities.3 
This infographic summarises three key 
pathways based on the recommendations 
of a multidisciplinary, patient-involving 
and multiprofessional specialist interest 
group on the investigation and manage-
ment of IIH.4
The basis of the specialist interest group 
included representation from neurology, 
neurosurgery, neuroradiology, ophthal-
mology, nursing, primary care doctors 
and patient representatives. Questions on 
PICO were defined and through a large 
Delphi group exercise; expertise was 
captured from a wide-reaching group of 
clinicians, thus reflecting practice from 
across the UK and internationally. The 
statements were then critically reviewed 
by key opinion leaders and by Associa-
tion of British Neurologists, British Asso-
ciation for the Study of Headache, the 
Society of British Neurological Surgeons 
and the Royal College of Ophthalmolo-
gists. This is the first consensus guidance 
for optimal management of IIH.4
Identification of papilloedema can 
be challenging, and clinicians should 
be aware of the differential diagnosis of 
pseudopapilloedema (figure 1). Once 
papilloedema is confirmed, it requires 
urgent investigations, including lumbar 
puncture, where the patient experience 
could be greatly improved.5 Symptoms of 
IIH are not pathognomonic, and hence 
it is essential to apply the diagnostic 
criteria, including excluding secondary 
causes, for a definite diagnosis.4 The 
lumbar puncture opening pressure was 
one key area of debate. Within the wider 
Delphi group, it was clear that there is a 
‘grey zone’ of lumbar puncture opening 
pressures between 25 cm cerebrospinal 
fluid (cmCSF) and 30 cmCSF, as to what 
each expert considered to be patholog-
ical, and this is reflected within the info-
graphic thermometer for lumbar puncture 
opening pressure (figure 1).
Principles of management need to 
address both the rapidity of the disease 
that may lead to visual loss in some 
and require surgical intervention and 
the morbidity of the headache that can 
develop in the majority, which substan-
tially affects the quality of life.6 Weight 
loss is currently the only established 
disease-modifying therapy7 and is noto-
riously difficult to achieve and maintain.
Evaluation of the headache phenotype 
is essential to target treatment and to help 
identify medication-overuse headache. 
Where there are features of migraine, topi-
ramate may be the first line in treatment, 
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Figure 1 Consensus Guideline in Adult Idiopathic Intracranial Hypertension: an infographic summary.  
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and recent evidence indicates that it has a significant 
intracranial pressure-lowering effect in rodents.8 Acute 
exacerbation of headache often leads to reinvestiga-
tion with lumbar puncture, and the collective expert 
opinion reflected that lumbar puncture provides only 
temporary relief, can lead in some to longer term 
complications9 and exacerbation of headache.10 In 
those with acute exacerbation of headache, optic 
nerve examination is essential, and in those found not 
to have papilloedema, investigation with lumbar punc-
ture and brain imaging is not required, so long as no 
other secondary causes of headache are suspected. The 
infographic illustrates the management of acute exac-
erbation of headache in IIH (figure 1).
Horizon scanning for IIH shows that research is 
active and that metabolic concepts may potentially 
provide more understanding of the cause and provide 
evidence for innovative therapeutic opportunities.11 A 
phase 2 randomised control trial with the first novel 
drug treatment for IIH has finished recruitment12; a 
phase 3 randomised control trial investigating the best 
method for weight loss is underway13; other surgical 
trials are in planning.
This infographic highlights three areas that are 
covered by the consensus guideline for adult IIH, 
which are: (1) investigation of papilloedema and 
diagnosis of IIH; (2) management strategies; and (3) 
investigation and management of acute exacerbation 
of headache in established IIH4 (figure 1).
Key points
 ► Cerebral venography is an essential part of the work-
up to exclude venous sinus thrombosis as a cause of 
papilloedema.
 ► Lumbar puncture opening pressure forms part of the 
diagnostic criteria; however, most clinicians feel there 
is a ‘grey zone’ between 25 cmCSF and 30 cmCSF, 
which may not be pathological.
 ► Those with fulminant or precipitous visual decline 
need urgent surgical treatment, preferably with a 
ventriculoperintoneal shunt.
 ► All patients diagnosed with idiopathic intracranial 
hypertension need sensitive and appropriate 
discussion regarding weight loss (the only disease-
modifying treatment).
 ► Those with acute exacerbation of headache do 
not require further neuroimaging or repeat lumbar 
puncture, unless there are red flag symptoms/signs 
of infection, or papilloedema with precipitous visual 
decline.
Correction notice This article has been corrected since it was 
published Online First. The provenance and peer review 
disclaimer incorrectly said the paper was not commissioned.
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